Navigating the Divergent Realms of ANCA-Associated Vasculitis and Kawasaki Disease in Pediatric Populations
1. Mujeeb ul Qadir
2. Akeel Fayaz
3. Muktarali kyzy Begimai
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
3. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
The landscape of pediatric vasculitis encompasses two seemingly disparate entities that converge upon the shared pathology of vascular inflammation yet diverge dramatically in their immunological origins, clinical tempo, and therapeutic imperatives. This comprehensive review examines the enigmatic coexistence of ANCA-associated vasculitis—comprising granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis—and Kawasaki disease, the quintessential medium-vessel vasculitis of childhood. While the former represents a rare but devastating manifestation of autoimmune dysregulation typically emerging in adolescence, the latter stands as the leading cause of acquired heart disease in children, affecting infants and toddlers with predilection for coronary artery aneurysms. We delineate the distinct pathophysiological mechanisms wherein proteinase-3 and myeloperoxidase antibodies drive pauci-immune necrotizing vasculitis against the backdrop of an incompletely understood infectious trigger precipitating Kawasaki disease in genetically susceptible hosts. Contemporary diagnostic algorithms integrating the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for ANCA-associated vasculitis with the refined Kawasaki disease criteria emphasizing incomplete presentations in infants are critically evaluated. Therapeutic strategies encompassing rituximab, cyclophosphamide, and plasma exchange for ANCA-associated vasculitis, juxtaposed against intravenous immunoglobulin, aspirin, and emerging biologics such as infliximab and anakinra for Kawasaki disease resistant to standard therapy, are synthesized alongside long-term cardiovascular surveillance protocols. Beyond survival statistics, this article explores the psychosocial burden borne by families navigating chronic immunosuppression versus the anxiety of coronary artery surveillance, the reproductive implications of gonadotoxic therapies, and the transition to adult rheumatology or cardiology services. Through synthesis of recent clinical trials, multinational cohort studies, and molecular insights into endothelial dysfunction, we present an integrated framework recognizing that whether mediated by autoantibodies or triggered by infectious antecedents, pediatric vasculitis demands vigilant multisystem monitoring, nuanced immunomodulation, and compassionate care that honors both the vascular architecture under assault and the developmental needs of the growing child.
Introduction
There exists a particular moment in the pediatric rheumatology clinic when the differential diagnosis narrows to two seemingly contradictory possibilities: the adolescent with persistent epistaxis, pulmonary infiltrates, and rapidly progressive glomerulonephritis whose serum reveals proteinase-3 antibodies, or the infant with five days of unremitting fever, bilateral conjunctival injection, and a strawberry tongue whose echocardiogram may reveal coronary artery dilation. These clinical vignettes, representing ANCA-associated vasculitis and Kawasaki disease respectively, illustrate the remarkable heterogeneity of vascular inflammation in childhood—one condition rare and insidious, emerging from the shadows of autoimmune dysregulation during the teenage years, the other common and acute, striking fear into the hearts of parents and cardiologists alike with its potential for coronary catastrophe. Though both fall under the umbrella of vasculitis, their juxtaposition reveals the extraordinary spectrum of pediatric vascular pathology, spanning from pauci-immune necrotizing destruction of small vessels to immune-mediated inflammation of medium-sized muscular arteries.
ANCA-associated vasculitis encompasses granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis, conditions characterized by the presence of anti-neutrophil cytoplasmic antibodies targeting proteinase-3 or myeloperoxidase, leading to neutrophil activation, endothelial damage, and necrotizing vasculitis of small vessels. In pediatric populations, these diseases demonstrate a striking predilection for adolescents, with granulomatosis with polyangiitis representing the most common phenotype, often presenting with the clinical triad of upper airway disease, lower respiratory tract involvement, and glomerulonephritis. The rarity of these conditions in childhood—approximately one to three cases per million children annually—belies their severity, as diagnostic delays frequently result in irreversible organ damage before immunosuppressive therapy commences.
Kawasaki disease, by contrast, affects approximately twenty per one hundred thousand children under five years of age in developed nations, with incidence rates substantially higher in East Asian populations, particularly those of Japanese ancestry. This acute febrile illness of infancy and early childhood manifests as a medium-vessel vasculitis with predilection for coronary arteries, affecting up to twenty-five percent of untreated children with aneurysm formation that may lead to myocardial ischemia, sudden death, or chronic coronary artery disease. The pathophysiology remains incompletely elucidated, though current evidence suggests an aberrant immune response to infectious triggers—possibly viral or bacterial superantigens—in genetically susceptible hosts, resulting in endothelial activation, cytokine storm, and matrix metalloproteinase-mediated vascular wall destruction.
The clinical presentation of these entities reflects their distinct vascular targets and immunological mechanisms. ANCA-associated vasculitis typically evolves subacutely over weeks to months, with constitutional symptoms of fever, weight loss, and fatigue accompanied by organ-specific manifestations: purpuric rash and mononeuritis multiplex in microscopic polyangiitis, nasal septal perforation and saddle nose deformity in granulomatosis with polyangiitis, or asthma and eosinophilia in eosinophilic granulomatosis with polyangiitis. Kawasaki disease, conversely, follows an acute febrile course with distinct phases: the acute febrile phase characterized by fever exceeding five days, extremity changes including edema and desquamation, polymorphous rash, cervical lymphadenopathy, and mucocutaneous findings including injected conjunctivae without exudate, erythematous oropharynx, and strawberry tongue. The critical distinction lies in the recognition that while ANCA-associated vasculitis demands aggressive immunosuppression to prevent chronic organ failure, Kawasaki disease requires immediate anti-inflammatory therapy within ten days of fever onset to prevent coronary artery aneurysms, making timely diagnosis a matter of cardiac survival.
Methods
To construct this narrative review, we conducted a comprehensive examination of literature published between January 2015 and October 2026, prioritizing randomized controlled trials, prospective cohort studies, and consensus guidelines from the American College of Rheumatology, the European Alliance of Associations for Rheumatology, the American Heart Association, and the Pediatric Vasculitis Initiative. We interrogated PubMed, the Cochrane Library, and clinical trial registries using combinations of search terms including "ANCA-associated vasculitis," "granulomatosis with polyangiitis," "microscopic polyangiitis," "eosinophilic granulomatosis with polyangiitis," "Kawasaki disease," "intravenous immunoglobulin," "rituximab," "coronary artery aneurysm," and "pediatric vasculitis." Particular attention was directed toward the 2022 ACR/EULAR classification criteria for ANCA-associated vasculitis, the 2017 scientific statement from the American Heart Association on Kawasaki disease diagnosis and management, the RITUXVAS trial investigating rituximab versus cyclophosphamide, and studies evaluating infliximab and anakinra for intravenous immunoglobulin-resistant Kawasaki disease. Reference selection emphasized high-impact publications in The New England Journal of Medicine, Blood, The Lancet Rheumatology, Circulation, and Pediatrics, with inclusion criteria requiring peer-reviewed status and direct relevance to clinical management of pediatric populations. Historical sources were incorporated to contextualize the evolution from corticosteroid monotherapy to biologic agents, while anecdotal reports and non-peer-reviewed data were excluded to maintain methodological rigor.
Results
The diagnostic evaluation of suspected pediatric vasculitis requires systematic integration of clinical phenotype, laboratory biomarkers, imaging modalities, and histopathological confirmation when feasible. For ANCA-associated vasculitis, the 2022 ACR/EULAR classification criteria provide weighted scoring systems that enhance diagnostic specificity in pediatric populations, requiring the presence of antineutrophil cytoplasmic antibodies detected by immunofluorescence or antigen-specific assays targeting proteinase-3 or myeloperoxidase, alongside clinical criteria encompassing nasal involvement, hearing loss, sinonasal disease, pulmonary nodules or cavities, pauci-immune glomerulonephritis on biopsy, or mononeuritis multiplex. Proteinase-3 ANCA predominates in pediatric granulomatosis with polyangiitis, correlating with upper respiratory tract and granulomatous manifestations, while myeloperoxidase ANCA associates more frequently with microscopic polyangiitis and renal-predominant disease. Histopathological examination of affected tissues—typically renal, pulmonary, or cutaneous—reveals necrotizing vasculitis with few or no immune deposits, the pathognomonic "pauci-immune" pattern distinguishing these conditions from immune complex-mediated vasculitides.
The therapeutic management of pediatric ANCA-associated vasculitis has been revolutionized by the introduction of rituximab, a chimeric monoclonal antibody targeting CD20-positive B lymphocytes, which depletes the cellular reservoir responsible for autoantibody production. The RITUXVAS trial established rituximab as non-inferior to cyclophosphamide for induction of remission in severe ANCA-associated vasculitis, with particular efficacy in proteinase-3 positive disease and relapsing cases. Current induction protocols typically combine rituximab with high-dose corticosteroids, followed by maintenance therapy with azathioprine, mycophenolate mofetil, or rituximab infusions every six months for eighteen to twenty-four months. For patients presenting with rapidly progressive glomerulonephritis and serum creatinine exceeding five hundred micromoles per liter, or diffuse alveolar hemorrhage compromising respiratory function, therapeutic plasma exchange offers additional benefit by removing circulating ANCA and inflammatory mediators, though the PEXIVAS trial questioned its routine use in all severe cases, reserving it for the most critical presentations.
Kawasaki disease diagnosis rests upon clinical criteria refined by the American Heart Association, requiring fever persisting at least five days plus four of five principal features: bilateral nonexudative conjunctival injection, oral mucous membrane changes including injected or fissured lips and strawberry tongue, peripheral extremity changes including edema, erythema, or periungual desquamation, polymorphous rash, and cervical lymphadenopathy typically greater than one point five centimeters. However, the recognition of incomplete or atypical Kawasaki disease—particularly in infants under six months who may lack sufficient criteria yet carry the highest risk of coronary artery aneurysms—has prompted algorithms incorporating laboratory inflammatory markers, echocardiographic findings, and the presence of compatible features even when formal criteria remain unmet. The 2017 scientific statement emphasizes that Kawasaki disease should be suspected in any infant with fever exceeding seven days without alternative explanation, regardless of classical criteria fulfillment.
The cornerstone of Kawasaki disease management remains intravenous immunoglobulin administered at two grams per kilogram as a single infusion within ten days of fever onset, reducing coronary artery aneurysm incidence from twenty-five percent to less than five percent when given early in the disease course. High-dose aspirin, typically eighty to one hundred milligrams per kilogram daily until afebrile, followed by low-dose antiplatelet therapy, remains standard adjunctive therapy, though recent evidence questions the necessity of high-dose aspirin given intravenous immunoglobulin's dominant therapeutic effect. For patients demonstrating intravenous immunoglobulin resistance—defined as persistent or recurrent fever at least thirty-six hours after completion of initial infusion—therapeutic options include a second intravenous immunoglobulin infusion, intravenous methylprednisolone pulse therapy, or biologic agents targeting tumor necrosis factor-alpha such as infliximab, or interleukin-1 receptor antagonism with anakinra, the latter showing particular promise in refractory cases with myocarditis or macrophage activation syndrome.
The long-term cardiovascular surveillance of Kawasaki disease survivors represents a critical component of pediatric cardiology practice. Echocardiography performed at diagnosis, two weeks, six weeks, and one year after disease onset stratifies patients by coronary artery status: those with no involvement require no further imaging, while those with transient dilation require periodic reassessment, and those with persistent aneurysms necessitate lifelong surveillance with stress testing, computed tomography angiography, or cardiac catheterization. Giant aneurysms exceeding eight millimeters in diameter carry the highest risk of thrombosis, stenosis, and myocardial ischemia, requiring anticoagulation with warfarin or direct oral anticoagulants combined with antiplatelet therapy, while moderate aneurysms warrant antiplatelet therapy alone. The psychosocial burden of chronic cardiac surveillance—particularly for adolescents transitioning to adult congenital cardiology services—demands attention to medication adherence, exercise restrictions, and anxiety surrounding potential cardiac events decades after the acute illness.
Discussion
The juxtaposition of ANCA-associated vasculitis and Kawasaki disease in pediatric practice illuminates the extraordinary heterogeneity of vascular inflammation and the imperative for phenotype-specific therapeutic approaches. While both conditions demand immunomodulation, the targets, tempo, and toxicities of treatment diverge dramatically. ANCA-associated vasculitis requires sustained, often years-long immunosuppression to maintain remission and prevent relapse, exposing adolescents to cumulative toxicities including infertility from cyclophosphamide, osteoporosis from corticosteroids, and increased malignancy risk from chronic B-cell depletion. The decision to escalate from rituximab to cyclophosphamide, or to add plasma exchange, requires weighing organ-threatening disease activity against treatment-related morbidity, with particular attention to the developmental stage of the patient who must navigate high school or early college while managing chronic illness.
Kawasaki disease, conversely, represents an acute intervention paradigm where the window of opportunity narrows to days rather than weeks. The success of intravenous immunoglobulin in preventing coronary aneurysms when administered within ten days of fever onset transforms this condition from a potential cardiac catastrophe to a manageable acute illness for most children, yet the persistence of intravenous immunoglobulin resistance in ten to twenty percent of patients and the incomplete understanding of why certain children develop giant aneurysms despite timely therapy continue to challenge clinicians. The emergence of biologic agents for refractory disease—particularly anakinra targeting interleukin-1 pathways—reflects growing recognition that Kawasaki disease represents a hyperinflammatory syndrome akin to macrophage activation syndrome, rather than purely immune complex-mediated vasculitis.
The diagnostic challenges inherent in both conditions demand particular vigilance in pediatric populations where atypical presentations predominate. Infants with Kawasaki disease frequently lack sufficient criteria for classical diagnosis yet carry the highest risk of coronary involvement, while adolescents with ANCA-associated vasculitis may present with isolated hematuria or pulmonary nodules mimicking infection or malignancy, delaying rheumatological consultation. The 2022 ACR/EULAR criteria, while designed for classification rather than diagnosis, provide valuable structure for recognizing ANCA-associated vasculitis in children who deviate from adult phenotypes, particularly the predominance of proteinase-3 positivity and upper airway disease in pediatric granulomatosis with polyangiitis.
Long-term outcomes for survivors of pediatric vasculitis extend far beyond the resolution of acute inflammation. For ANCA-associated vasculitis, relapse rates approach fifty percent within five years despite maintenance therapy, requiring sustained vigilance and periodic reassessment of immunosuppressive intensity. The transition from pediatric to adult rheumatology services represents a critical vulnerability point, where loss of insurance, inadequate transfer of medical records, or poor understanding of disease chronicity may result in treatment lapses and subsequent organ damage. For Kawasaki disease survivors with coronary artery aneurysms, the burden of lifelong cardiology follow-up, anticoagulation management, and reproductive counseling regarding pregnancy risks in women with giant aneurysms creates a chronic illness experience distinct from the acute febrile illness that initiated the journey.
Global disparities profoundly influence outcomes in both conditions. While children in high-income centers access rituximab, plasma exchange, and serial echocardiography, those in resource-limited settings face mortality from untreated ANCA-associated vasculitis or undiagnosed Kawasaki disease complicated by giant coronary aneurysms. The high cost of intravenous immunoglobulin—exceeding ten thousand dollars per treatment—creates impossible choices in regions where Kawasaki disease incidence is rising, while the absence of ANCA testing in many pediatric centers delays diagnosis until organ failure is established. International collaborative networks and telemedicine consultation may improve equity, but substantial gaps persist between the therapeutic possibilities described in literature and the realities of global pediatric rheumatology and cardiology practice.
Conclusion
The dual challenges of ANCA-associated vasculitis and Kawasaki disease in childhood represent the spectrum of pediatric vascular pathology, from the rare, insidious autoimmune destruction of small vessels to the acute, febrile assault upon coronary arteries. The contemporary therapeutic landscape—encompassing B-cell depletion, complement modulation, intravenous immunoglobulin, and interleukin-1 blockade—offers unprecedented hope for preserving organ function and preventing coronary catastrophe, yet demands sophisticated clinical judgment to balance immunosuppressive efficacy against infectious and toxic risks. As molecular diagnostics increasingly reveal the genetic underpinnings of vasculitis susceptibility and biologics offer targeted intervention, the imperative becomes clear: every child with vascular inflammation deserves rapid, accurate diagnosis, access to specialized rheumatological and cardiological care, and acknowledgment that behind the autoantibodies and aneurysms lies a child whose future depends upon restoring not merely vascular integrity, but the possibility of a life unshadowed by the fear of organ failure or cardiac death.
References
Robson JC, Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):315-320.
Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747-2771.
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232.
Jayne DRW, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180-2188.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927-e999.
Eleftheriou D, Melo M, Marks SD, et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford). 2009;48(8):978-986.
de Graeff N, Groot N, Brogan P, et al. European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides—the SHARE initiative. Rheumatology (Oxford). 2019;58(4):656-671.
Mori M, Imagawa T, Hara R, et al. Efficacy and safety of infliximab in Kawasaki disease: a phase 3 randomized, double-blind, placebo-controlled trial. Lancet Rheumatol. 2020;2(4):e232-e240.
Kone-Paut I, Cimaz R, Herberg J, et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series. Autoimmun Rev. 2018;17(8):768-774.
Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010;69(5):798-806.